Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Weekapaug who wrote (2291)	10/13/1997 11:57:00 AM
From: margie	of 6136

There are many interesting studies being presented 10/11-10/15/97 at the conference in Hamburg, Germany: SIXTH EUROPEAN CONFERENCE ON CLINICAL ASPECTS AND TREATMENT OF HIV-INFECTION. Agouron had a study accepted for a late breaking session at this meeting, re: BID (twice daily dosing) at 1250 mg in combination with two reverse transcriptase inhibitors, from a preliminary small study. A larger BID study including 200 patients is expected to be presented in Chicago in early February. According to analysts, Agouron has provided reassurance that, in contrast with modestly positive trends in recent IMS prescription data, wholesalers orders in the past few weeks have reached record levels. Monthly orders from wholesalers have steadily increased since the market launch and there is no indication of a slowdown. Paine Webber has raised 12 month price target to $75. Abstracts from the ongoing Hamburg conference can be viewed at euro-aids97.com Go to: The Abstracts, then Titles, for a list of all abstracts, or search: Inclusive: Nelfinavir mesylate (or) Exclusive: Viracept (and) Category: Text Some of interest are: A COMPARISON OF SAFETY AND EFFICACY OF VIRACEPT (NELFINAVIR MESYLATE) IN HIV-INFECTED CHILDREN AND ADULTS - Abstract 591 - DURABILITY OF VIROLOGICAL RESPONSE IN PATIENTS TREATED WITH VIRACEPT (NELFINAVIR) IN COMBINATION WITH ZIDOVUDINE AND LAMIVUDINE - 410 - LONG-TERM VIROLOGICAL AND IMMUNOLOGICAL RESPONSE TO TREATMENT WITH VIRACEPT (NELFINAVIR MESYLATE) IN COMBINATION WITH ZIDOVUDINE AND LAMIVUDINE - 210 - NELFINAVIR IN THE TREATMENT OF HIV INFECTED ADULTS: PATTERNS OF USE IN THE FRENCH COMPASSIONATE USE PROGRAMME (ATU). - 823 - Interesting to note that Viracept is prescribed by 208 physicians in 91 hospitals in France RENAL DYSFUNCTION IN AN HIV+ PATIENT TREATED WITH INDINAVIR - 807 - STUDY OF PROTEASE INHIBITORS IN COMBINATION IN EUROPE (SPICE) - 209 - THE EFFECT OF NELFINAVIR ON PLASMA SAQUINAVIR LEVELS - 455 DURABILITY OF VIROLOGICAL RESPONSE IN PATIENTS TREATED WITH VIRACEPT (NELFINAVIR) IN COMBINATION WITH ZIDOVUDINE AND LAMIVUDINE - 410 - The studies below do not include Viracept (not aproved in Europe yet), but interesting. ACCEPTANCE AND COMPLIANCE OF ANTIRETROVIRAL THERAPY AND SURVIVAL -366 DO GENOTYPIC CHANGES DURING PROTEASE INHIBITOR (PI) FAILURE PREDICT RESPONSE TO A SUBSEQUENT PI-CONTAINING COMBINATION? -411 STRATEGIES FOR SWITCHING ANTIRETROVIRAL THERAPY: VIRAL LOAD AT SWITCH AND ITS CORRELATION TO LONGTERM OUTCOME. A PROSPECTIVE MULTICENTER EVALUATION (IDKF_GASG_022) - 382 - THE ANTIVIRAL EFFECT OF RITONAVIR AND SAQUINAVIR IN COMBINATION AMONG HIV INFECTED ADULTS: RESULTS FROM A COMMUNITY BASED STUDY - 437 - TOLERABILITY OF THE PROTEASE INHIBITORS - 447 - TOLERABILITY OF PROTEASE INHIBITORS DURING THERAPY FOR HIV INFECTION - 443 -

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next